Login to Your Account



GSK yes on Adaptimmune option adds $61M for TCR effort

By Randy Osborne
Staff Writer

Thursday, September 7, 2017

Adaptimmune Therapeutics plc CEO James Noble said Glaxosmithkline plc exercised its option "much earlier than they needed to," exclusively licensing rights to research, develop and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription